Thursday, October 10, 2024
11:00 AM Eastern Daylight Time
Gene therapy based therapeutics offer revolutionary ways of treating and curing genetic disorders. CMC plays a crucial part, however it is faced with complex manufacturing processes and the intrinsic complexity of the genetic therapeutics themselves.
In this webinar, learn about key pre-quality attributes in AAV manufacturing and the cognate landscape of technologies analyzing them. There is a high need for more sophisticated methods for improving and deepening the understanding of the process and product.
Roland Pach holds a doctoral degree in molecular parasitology from the University Fribourg, where he analysed the intracellular trafficking of transgenic RNA in trypanosomes.
At Roche, Roland is the global CMC analytical technical lead in the cancer vaccines and cell and gene therapy (CGT) area for more than 15 years. In his assigned area, he represents Roche-Genentech in external development projects, at industrial consortia like CGT BioPhorum and at numerous successful due diligence projects of in-licensing candidates or at merger of companies in the CGT fields. As editor and author at Springer Nature, he published several white papers and articles describing the current challenges of manufacturing and analysis of CGT drug products.
In his second role at Roche as global technical development leader, he successfully led new formats like immunotoxins from pre-clinics into entry to human (EiH, Phase 1).
